Patent · US Active

Personalized medicine for the prediction of therapy targeting the hedgehog pathway

US9655909B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Mien-Chie Hung · Houston, US
Yan Wang · Jingwei, CN
Jaffer Ajani · Houston, US

Key dates

Filing date	Jan 14, 2013
Grant date	May 23, 2017
Priority date	—
Expiry date	May 12, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods and composition for tumor therapy, especially esophageal adenocarcinoma (EAC), are described. For example, in certain aspects methods for determining Hedgehog and mTOR signaling pathway status to select patients for administering a combination therapy of Hedgehog and mTOR signaling inhibitors are described. Furthermore, the invention provides compositions that involve testing kits for determining signaling status.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.